192 related articles for article (PubMed ID: 18097642)
1. Exploiting signal transduction pathways in acute myelogenous leukemia.
Perl AE; Carroll M
Curr Treat Options Oncol; 2007 Aug; 8(4):265-76. PubMed ID: 18097642
[TBL] [Abstract][Full Text] [Related]
2. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Garcia JS; Stone RM
Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
4. Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.
Karp JE; Lancet JE
Biologics; 2008 Sep; 2(3):491-500. PubMed ID: 19707379
[TBL] [Abstract][Full Text] [Related]
5. Quizartinib (AC220): a promising option for acute myeloid leukemia.
Zhou F; Ge Z; Chen B
Drug Des Devel Ther; 2019; 13():1117-1125. PubMed ID: 31114157
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.
Gotlib J
Curr Hematol Rep; 2005 Jan; 4(1):77-84. PubMed ID: 15610664
[TBL] [Abstract][Full Text] [Related]
7. The Future of Targeting FLT3 Activation in AML.
Leick MB; Levis MJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):153-167. PubMed ID: 28421420
[TBL] [Abstract][Full Text] [Related]
8. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Roskoski R
Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
Martinelli G; Iacobucci I; Paolini S; Ottaviani E
Clin Adv Hematol Oncol; 2008 Apr; 6(4):303-10. PubMed ID: 18496498
[TBL] [Abstract][Full Text] [Related]
10. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development.
Kiyoi H; Kawashima N; Ishikawa Y
Cancer Sci; 2020 Feb; 111(2):312-322. PubMed ID: 31821677
[TBL] [Abstract][Full Text] [Related]
11. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.
Fathi AT; Chen YB
Eur J Haematol; 2017 Apr; 98(4):330-336. PubMed ID: 28000291
[TBL] [Abstract][Full Text] [Related]
12. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
Sternberg DW; Licht JD
Curr Opin Hematol; 2005 Jan; 12(1):7-13. PubMed ID: 15604885
[TBL] [Abstract][Full Text] [Related]
14. Farnesyl transferase inhibitors in myeloid malignancies.
Lancet JE; Karp JE
Blood Rev; 2003 Sep; 17(3):123-9. PubMed ID: 12818222
[TBL] [Abstract][Full Text] [Related]
15. Molecularly targeted therapy in acute myeloid leukemia.
Gill H; Leung AY; Kwong YL
Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
[TBL] [Abstract][Full Text] [Related]
16. New agents for the treatment of acute myeloid leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2006; 19(2):311-20. PubMed ID: 16516128
[TBL] [Abstract][Full Text] [Related]
17. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
[TBL] [Abstract][Full Text] [Related]
18. Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges.
Ling Y; Zhang Z; Zhang H; Huang Z
Curr Pharm Des; 2017 Nov; 23(29):4303-4310. PubMed ID: 28671056
[TBL] [Abstract][Full Text] [Related]
19. New treatment for acute myelogenous leukemia.
DiNardo CD; Cortes JE
Expert Opin Pharmacother; 2015 Jan; 16(1):95-106. PubMed ID: 25480777
[TBL] [Abstract][Full Text] [Related]
20. Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
Tickenbrock L; Müller-Tidow C; Berdel WE; Serve H
Expert Opin Emerg Drugs; 2006 Mar; 11(1):153-65. PubMed ID: 16503833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]